Durvalumab plus Chemotherapy in Untreated Patients with Extensive-Stage Small Cell Lung Cancer - CANTABRICO

Study identifier:D419QC00005

ClinicalTrials.gov identifier:NCT04712903

EudraCT identifier:2020-002328-35

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Spain (CANTABRICO).

Medical condition

Small Cell Lung Carcinoma Extensive Disease

Phase

Phase 3

Healthy volunteers

Yes

Study drug

Durvalumab, Cisplatin, Etoposide, Carboplatin

Sex

All

Actual Enrollment

101

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 16 Dec 2020
Primary Completion Date: 21 Jun 2023
Study Completion Date: 21 Jun 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria